CareDx reported a strong Q4 2019 with a 52% increase in revenue compared to Q4 2018. The company also saw growth in testing services, product revenue, and digital revenue. While GAAP net loss was reported, non-GAAP net income and adjusted EBITDA were positive.
Total revenue reached $35.8 million, a 52% year-over-year increase.
Over 14,000 patient results were provided during the quarter.
Over 30 U.S.-based transplant centers have adopted an AlloSure Kidney testing protocol.
GAAP net loss was $4.8 million, while non-GAAP net income was $1.6 million.
CareDx expects revenue to be in the range of $165 million to $168 million for the full year 2020.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance